Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
United European Gastroenterol J. 2020 Jun;8(5):536-543. doi: 10.1177/2050640620909675. Epub 2020 Feb 26.
Type-C hepatic encephalopathy is a complex neurological syndrome, characteristic of patients with liver disease, causing a wide and complex spectrum of nonspecific neurological and psychiatric manifestations, ranging from a subclinical entity, minimal hepatic encephalopathy, to a deep form in which a complete alteration of consciousness can be observed: overt hepatic encephalopathy. Overt hepatic encephalopathy occurs in 30-40% of patients. According to the time course, hepatic encephalopathy is subdivided into episodic, recurrent and persistent. Diagnostic strategies range from simple clinical scales to more complex psychometric and neurophysiological tools. Therapeutic options may vary between episodic hepatic encephalopathy, in which it is important to define and treat the precipitating factor and hepatic encephalopathy and secondary prophylaxis, where the standard of care is non-absorbable disaccharides and rifaximin. Grey areas and future needs remain the therapeutic approach to minimal hepatic encephalopathy and issues in the design of therapeutic studies for hepatic encephalopathy.
慢性肝脏性脑病是一种复杂的神经综合征,以肝病患者为特征,导致广泛而复杂的非特异性神经和精神表现,从亚临床实体、轻微肝脏性脑病到完全意识改变的深层形式:显性肝脏性脑病。显性肝脏性脑病发生在 30-40%的患者中。根据时间过程,肝脏性脑病可分为发作性、复发性和持续性。诊断策略范围从简单的临床量表到更复杂的心理测量和神经生理学工具。治疗选择可能在发作性肝脏性脑病之间有所不同,在这种情况下,重要的是定义和治疗诱发因素和肝脏性脑病,以及继发性预防,其中标准的护理是非吸收性双糖和利福昔明。最小肝脏性脑病的治疗方法和肝脏性脑病治疗研究设计中的问题仍然存在灰色地带和未来的需求。